Background
Cells of the mononuclear phagocytic system, monocytes and macrophages, are found in every tissue of the body and regulate infections, inflammation, and tissue repair, and are critical in the protection from, or development of, autoimmune diseases, asthma, fibrosis, and cancer [
1]. Tissue resident macrophages derive from progenitor cells that develop in the fetal yolk sac and fetal liver, whereas circulating monocytes are bone marrow-derived cells that leave the blood, enter tissues, and then differentiate into macrophages during inflammation, infection, or tissue damage [
2]. There are different types of macrophages such as M1 inflammatory macrophages, and M2 remodeling/fibrotic (M2a) or resolving/immune-regulatory (M2c; sometimes called Mreg) macrophages [
3]. Although many markers have been proposed that discriminate these subsets, there are no definitive markers to identify macrophage subtypes [
4]. In addition, as macrophages change their phenotypic markers and physiology when exposed to different environmental signals, macrophage phenotypes may be more of a series of overlapping subsets or a continuum, rather than defined and permanent subsets [
5].
In persistent diseases, macrophages can be either activated to drive a disease process, or either absent or suppressed and therefore unable to aid in the resolution of a condition [
1]. In tuberculosis, Leishmaniasis, trypanosome infections, and some tumors, the macrophages have an M2a or M2c phenotype, and it has been hypothesized that shifting these to an M1 phenotype could be therapeutic [
1]. Conversely, in fibrosis, the macrophages have an M2a pro-fibrotic phenotype, and shifting these to an M2c phenotype could be therapeutic [
1,
6]. Understanding, and being able to manipulate, macrophage differentiation could have a significant impact on a wide variety of diseases.
Pentraxins are secreted proteins that bind to, and promote efficient clearance of, microbial pathogens and cellular debris during infection, inflammation, and tissue damage [
7]. Pentraxins also regulate macrophage responses. The pentraxin serum amyloid P (SAP) is a constitutive component of plasma and drives monocytes and macrophages to a M2c phenotype, as defined by upregulation of the potent anti-inflammatory and anti-fibrotic cytokine IL-10 [
8‐
10]. In animal models, SAP inhibits fibrosis and promotes disease resolution by activating the CD209 receptor [
11], activating Fcγ receptors (FcγR) [
8,
11,
12] and by potentiating extracellular accumulation of IL-10 [
6,
8,
11]. In contrast to SAP, the pentraxin CRP has been thought to induce a M1 phenotype [
13]. Serum levels of human CRP increase up to a thousand fold during infection and inflammation [
14], and elevated serum CRP levels are a biomarker for predicting inflammatory diseases [
15]. In animals, overexpression of CRP strongly potentiates inflammation and fibrosis [
16]. However, CRP can inhibit experimental allergic encephalomyelitis (EAE) and kidney inflammation by macrophage- and IL-10-dependent mechanisms [
17,
18]. A third pentraxin, PTX3, is upregulated during inflammation in humans, but in mice appears to be pro-inflammatory in some models and limits inflammation in other models, and its effects on human or mouse macrophages is unclear [
7,
19]. These data indicate that pentraxins have complex and important roles in inflammation and tissue damage. Pentraxins not only act on cells as independent molecules but also in association with a variety of ligands [
7]. SAP, CRP, and PTX3 all bind the complement component C1q, and promote phagocytosis of complement-bound bacteria [
20‐
22]. Additional pentraxin ligands include complement component Factor H, which binds CRP and PTX3, and mannose-binding lectin (MBL), which binds SAP and PTX3 [
7,
23,
24].
As circulating monocytes, differentiating macrophages, and tissue resident macrophages are exposed to the three pentraxins and their ligands during infection, inflammation, and tissue damage, we assessed what effect pentraxins and their ligands have on macrophages. In this report, we show that pentraxins and their ligands have distinct effects on monocyte differentiation into macrophages and macrophage priming from one subtype to another subtype. In addition, we show that CRP can induce production of the anti-inflammatory cytokine IL-10.
Discussion
Pentraxins regulate macrophage responses, either by enhancing phagocytosis, by regulating complement activation, or by directly binding to receptors to alter macrophage differentiation and polarization [
10,
11,
52]. In this report, we found that CD163, CD169, and CD206 expression was differentially regulated by pentraxins, and that the pentraxin ligands Factor H, MBL, and C1q altered some of these responses for CD169 and CD206. In addition, we found that CRP was a potent inducer of IL-10 production in monocytes and macrophages cultured in the presence of M-CSF but not GM-CSF.
We found that most of the published macrophage polarization markers were unaltered by culturing cells in the presence of the pentraxins, even though these same markers were expressed differentially by macrophages using standard polarization conditions. These data suggest that pentraxin regulation of macrophage polarization is more subtle than a straightforward M1/M2a/M2c scheme and more akin to the view of macrophage polarization as a continuum[
5]. In addition, we found that the presence of Factor H, MBL, and C1q altered the expression of macrophage markers induced by pentraxins, such that C1q augmented the expression of CD169 by SAP, but C1q inhibited CD169 and CD206 expression induced by PTX3. Several groups including our own have previously shown that SAP and PTX3 can promote CD206 expression, but the observation that MBL and C1q can counteract these effects again suggests that experiments with a single pentraxin concentration do not adequately represent the environment found at sites of inflammation.
CRP is generally thought of as being an inflammatory mediator, due to its upregulation during infection and the correlation of high CRP levels with poor prognosis in persistent inflammatory conditions such as cardiovascular disease [
14]. However, others have argued that the effect of CRP is more subtle and the concentration of CRP present in a lesion, the presence of co-factors such as bacterial products and complement pathway proteins, and the site of tissue response may determine the pro- or anti-inflammatory nature of CRP [
7,
17]. Several reports also indicate that CRP can promote the production of the anti-inflammatory cytokine IL-10, suggesting that elevated CRP levels may by a means to downregulate inflammation [
17,
18,
53,
54]. The effect of CRP may be further complicated by the relative levels of CRP in the circulation compared to the tissue or inflammatory site, as transgenic mice expressing CRP in lesions have differential responses to mice with high levels of systemic CRP [
55].
The role of PTX3 in regulating inflammation is also dependent on spatial and temporal conditions [
7]. PTX3 can reduce platelet activation and neutrophil migration during the early stages of inflammation, and bind complement component proteins (such as C1q, MBL, and Factor H), to limit tissue injury [
56,
57]. However, increased PTX3 levels can exacerbate persistent and autoimmune diseases, such as chronic heart and lung diseases [
58‐
60]. Our observations that MBL and C1q can reverse PTX3-induced CD169 and CD206 expression suggest that both local and systemic concentrations of pentraxin ligands will have a profound effect on macrophage phenotype and function.
The four proteins regulated by pentraxins were the hemoglobin-haptoglobin complex receptor CD163, the surface receptors CD169 and CD206, and the anti-inflammatory cytokine IL-10. CD163 is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and is exclusively expressed in monocytes and macrophages [
61]. CD163 is a receptor involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages, and may thereby protect tissues from free hemoglobin-mediated oxidative damage [
62]. CD163 expression is upregulated by glucocorticoids and IL-10, and downregulated by LPS, TNF, and GM-CSF, suggesting that CD163 is a marker for alternatively activated macrophages [
63,
64]. However, CD163 positive macrophages are frequently found in tissue samples from chronic inflammation, and high levels of soluble CD163 are present in plasma from a wide range of inflammatory diseases [
65‐
67].
CD169, also known as Sialoadhesin or Siglec-1, is a lectin that binds to proteins with sialic acid residues, and is expressed by subsets of macrophages in secondary lymphoid organs (spleen and lymph nodes) and in tissues exposed to environmental antigens (lung, GI tract, and liver) [
46]. CD169 appears to promote the phagocytosis of pathogens, leading to enhanced immune responses, but inhibits autoimmune responses [
68]. However, increased CD169 expression promotes macrophage uptake of pathogens to augment adaptive T cell and B cell responses, but increased CD169 is also associated with an increased risk of autoimmune and cardiovascular disease [
46,
69,
70]. These data suggest that the local and systemic concentrations of SAP, PTX3, C1q, and MBL will ultimately regulate CD169 expression and function.
CD206, also known as the macrophage mannose receptor is a lectin that binds to mannose, N-acetylglucosamine, and fucose sugars on molecules, but only in the presence of calcium [
71]. CD206 is also expressed by specific subsets of macrophages, including lung alveolar macrophages and spleen, lymph node and bone marrow macrophages, but in different anatomical sites to macrophages expressing CD169 [
72]. CD206 recognition of bacteria without bound complement components (unopsonized) suppresses macrophage activation, whereas macrophage activation does occur when bacteria are opsonized and therefore bind receptors on macrophages other than CD206 [
73‐
75]. This appears to be a mechanism to prevent inflammatory responses against commensal bacteria, such as in in the lung [
42].
The expression of CD163, CD169, and CD206 on monocyte/macrophages appears to be regulated by a variety of factors including cytokines, with interferons and TNFα preventing or downregulating expression, and IL-4 and IL-10 upregulating expression of these 3 receptors [
46,
76,
77]. In addition, CD169 binds sialic acid residues, and CD206 binds mannose residues on pentraxins [
7], and both receptors appear to interact with Fc receptors to regulate Fc receptor signaling, internalization, and recycling [
46,
78]. Therefore, pentraxins may regulate the expression of these three receptors either by altering the cytokine milieu and/or by directly binding to the receptors, and the presence of the ligands may alter these processes.
IL-10 is an anti-inflammatory cytokine released by many cells, including macrophages and epithelial cells, in response to Fcγ receptor and CD209 (DC-SIGN) activation by IgG, SAP, and CRP [
8,
11,
17,
53,
79]. In macrophages, the production of IL-10 appears to be dependent on FcγR ligation, leading to ERK activation, which in turn causes remodeling of the chromatin at the IL-10 locus, making it more accessible to transcription factors [
80]. In IL-10 knockout mice, the protective effects of CRP and SAP on inflammation, nephritis, EAE, and lung fibrosis is reduced or absent, suggesting that these systemic pentraxins can act to quench ongoing inflammatory responses [
11,
17,
18,
53,
55]. As SAP, in most animals, is relatively constant and CRP is the acute phase response proteins (whereas in mice the situation is revered), these data also suggest that the two pentraxins may cooperate to regulate inflammation [
7]. The situation with PTX3 is different, as PTX3 does not appear to stimulate IL-10 production, but PTX3 production is stimulated by IL-10 [
7]. This suggests that the upregulation of PTX3 following inflammation may in part be modulated by SAP and CRP-induced IL-10 production, suggesting a feedback loop between the three pentraxins.
In health, the systemic levels of Factor H, MBL, and C1q are relatively constant [
47‐
51]. However, during inflammation the local activation of complement and the presence of bacteria and cell debris can lead to a local reduction in Factor H, MBL, and C1q levels, whereas the levels of CRP and PTX3 may increase (due to systemic and local production) at these same sites [
7,
81]. In addition, either a genetic deficiency of C1q or Factor H, or reduced serum concentrations due to increased consumption and/or neutralization by autoantibodies, leads to activated macrophages and is a major susceptibility factor for the development of systemic lupus erythematosus (SLE) [
82‐
84]. Similar MBL deficiencies lead to increased infection by influenza and exaggerated macrophage activation and increases in inflammatory cytokines, such as IL-1β and TNFα [
85‐
87].